Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

No clinical efficacy or safety issues raised
Citius committed to working toward approval
CRANFORD, N.J., July 29, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc.  today announced that the U.S....

Related Keywords

Japan ,Ilanit Allen ,Leonard Mazur ,Greg Salsburg ,Company Biologics License Application ,Securities Exchange ,Exchange Commission ,Citius Pharmaceuticals Inc ,Company Nasdaq ,Prnewswire Citius Pharmaceuticals Inc ,Drug Administration ,Complete Response Letter ,Biologics License Application ,Citius Pharmaceuticals ,Fast Track ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,